[go: up one dir, main page]

US20020007063A1 - Electronegatively substituted pyrimidines and intermediates leading to RNFX - Google Patents

Electronegatively substituted pyrimidines and intermediates leading to RNFX Download PDF

Info

Publication number
US20020007063A1
US20020007063A1 US09/911,640 US91164001A US2002007063A1 US 20020007063 A1 US20020007063 A1 US 20020007063A1 US 91164001 A US91164001 A US 91164001A US 2002007063 A1 US2002007063 A1 US 2002007063A1
Authority
US
United States
Prior art keywords
bis
difluoramino
group
regioisomer
propanediamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/911,640
Other versions
US6395899B2 (en
Inventor
Robert Chapman
Ba Nguyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/911,640 priority Critical patent/US6395899B2/en
Publication of US20020007063A1 publication Critical patent/US20020007063A1/en
Application granted granted Critical
Publication of US6395899B2 publication Critical patent/US6395899B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/04Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12Nitrogen atoms not forming part of a nitro radical
    • C07D239/18Nitrogen atoms not forming part of a nitro radical with hetero atoms attached to said nitrogen atoms, except nitro radicals, e.g. hydrazine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms

Definitions

  • This invention involves the calculated performance improvements expected from a particularly new class of compounds, geminal-bis(difluoramino)-substituted heterocyclic nitramines, when formulated into explosives and propellants. Further, this invention involves 5,5-bis(difluoramino)hexahydropyrimidine derivatives, related geminal-bis(difluoramino)alkylene derivatives, and novel precursors to these new derivatives, by the use of certain key intermediates which allow formation of this target structural subcomponent.
  • R 2 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl.
  • RNFX by Miller, exists when R 2 is hydrogen.
  • This invention involves novel and nonintuitive methods for the preparation of certain derivatives of 2,2-bis(difluoramino)-N-nitro-1,3-propanediamine which are suitable precursors leading to RNFX.
  • the synthesis of certain examples of this class of compounds is difficult and nonintuitive.
  • the certain examples that are particularly synthetically difficult are molecules that incorporate the geminal-bis(difluoramino)alkylene [C(NF 2 ) 2 ] component and the nitramine component [N—NO 2 ] in close proximity, especially when separated by only a methylene (CH 2 ) link in order to maintain a low fuel-to-oxidizer component ratio and concomitantly high oxygen balance in the product molecule.
  • RNFX a specific member of a general class of compounds with the substructure 2,2-bis(difluoramino)-N-nitro-1,3-propanediamine.
  • RNFX is produced by the use of key intermediates which allow formation of the target structural subcomponents, 2,2-bis(difluoramino)-N-nitro-1,3-propanediamine and a more specific substructure of 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine, which has the following structure:
  • this invention comprises certain unprecedented nitramides and nitramines suitable for conversion to RNFX and a variety of other difluoramino-substituted heterocyclic nitramines.
  • An important aspect of the present invention is the substitution on hetero cyclic precursors' nitrogen atoms and intermediate nitramides' nitrogen atoms.
  • the nitrogen atoms of heterocyclic precursors (such as pyrimidines) must be suitably substituted, or “protected,” during the process of difluoramination to allow this process to proceed to geminal-bis(difluoramino)alkylene derivatives.
  • An object of this invention is to create a novel explosive and propellant involving geminal-bis(difluoramino)-substituted heterocyclic nitramines.
  • Another object of this invention is to create a novel method of producing 5,5-bis(difluoramino)hexahydro-1,3-dinitropyrimidine using electronegatively substituted pyrimidines and other novel intermediates leading to RNFX.
  • Z 1 is selected from the group consisting of halosulfonyl, polyhaloalkanesulfonyl, polyhaloarenesulfonyl, a regioisomer of fluoroarenesulfonyl, polyhaloarenesulfonyl, a regioisomer of cyanoarenesulfonyl, polycyanoarenesulfonyl, a regioisomer of nitroarenesulfonyl, and polynitroarenesulfonyl.
  • the regioisomer of fluoroarenesulfonyl is selected from the group consisting of 2-, 3- and 4-fluoro-substituted arenesulfonyl
  • the regioisomer of cyanoarenesulfonyl is selected from the group consisting of 2-, 3- and 4-cyano-substituted arenesulfonyl
  • the regioisomer of nitroarenesulfonyl is selected from the group consisting of 2-, 3- and 4-nitro-substituted arenesulfonyl.
  • a tetrahydropyrimidin-5(4H)-one is a necessary precursor to a 5,5-bis(difluoramino)hexahydropyrimidine, based on the known conversion of ketone carbonyl groups by reaction with difluoramine or difluorosulfamic acid in the presence of a strong acid.
  • the nitrogen-protecting groups chosen for the new pyrimidine intermediates and precursors are certain sulfonyl substituents.
  • the particular sulfonyl substituents are chosen from a group that favorably affects the basicity of the pyrimidine nitrogens to make them less basic than the oxygen sites in the pyrimidine intermediates, in order to allow difluoramination of the carbonyl oxygens to proceed to geminal-bis(difluoramino)alkylene derivatives.
  • Suitable intermediates leading to tetrahydropyrimidin-5(4H)-ones include hexahydro-5-pyrimidinols (including their oxygen-protected derivatives) and hexahydro-5-(methylene)pyrimidines.
  • These novel N-sulfonylpyrimidine derivatives include hexahydro-5-pyrimidinols having the structure:
  • Z 1 is selected from the group consisting of halosulfonyl, polyhaloalkanesulfonyl, polyhaloarenesulfonyl, a regioisomer of fluoroarenesulfonyl, polyhaloarenesulfonyl, a regioisomer of cyanoarenesulfonyl, polycyanoarenesulfonyl, a regioisomer of nitroarenesulfonyl, and polynitroarenesulfonyl.
  • the regioisomer of fluoroarenesulfonyl is selected from the group consisting of 2-, 3- and 4-fluoro-substituted arenesulfonyl
  • the regioisomer of cyanoarenesulfonyl is selected from the group consisting of 2-, 3- and 4-cyano-substituted arenesulfonyl
  • the regioisomer of nitroarenesulfonyl is selected from the group consisting of 2-, 3- and 4-nitro-substituted arenesulfonyl.
  • R 1 is selected from the group consisting of hydrogen and an alcohol-protecting group.
  • novel N-sulfonylpyrimidine derivatives also include hexahydro-5-(methylene)pyrimidines having the following structure:
  • Z 1 is selected from the group consisting of halosulfonyl, polyhaloalkanesulfonyl, polyhaloarenesulfonyl, a regioisomer of fluoroarenesulfonyl, polyhaloarenesulfonyl, a regioisomer of cyanoarenesulfonyl, polycyanoarenesulfonyl, a regioisomer of nitroarenesulfonyl, and polynitroarenesulfonyl.
  • the regioisomer of fluoroarenesulfonyl is selected from the group consisting of 2-, 3- and 4-fluoro-substituted arenesulfonyl
  • the regioisomer of cyanoarenesulfonyl is selected from the group consisting of 2-, 3- and 4-cyano-substituted arenesulfonyl
  • the regioisomer of nitroarenesulfonyl is selected from the group consisting of 2-, 3- and 4-nitro-substituted arenesulfonyl.
  • a hexahydro-5-(methylene)pyrimidine is utilized as the intermediate leading to a tetrahydropyrimidin-5(4H)-one.
  • the production of hexahydro-5-(methylene)pyrimidines is accomplished as follows:
  • Z 1 is selected from the group consisting of halosulfonyl, polyhaloalkanesulfonyl, polyhaloarenesulfonyl, a regioisomer of cyanoarenesulfonyl, polycyanoarenesulfonyl, a regioisomer of nitroarenesulfonyl, and polynitroarenesulfonyl.
  • the regioisomer of fluoroarenesulfonyl is selected from the group consisting of 2-, 3- and 4-fluoro-substituted arenesulfonyl
  • the regioisomer of cyanoarenesulfonyl is selected from the group consisting of 2-, 3- and 4-cyano-substituted arenesulfonyl
  • the regioisomer of nitroarenesulfonyl is selected from the group consisting of 2-,3- and 4-nitro-substituted arenesulfonyl.
  • Hexahydro-5-pyrimidinols and hexahydro-5-(methylene)pyrimidines are suitable intermediates that can be converted to tetrahydropyrimidin-5(4H)-one precursors.
  • hexahydro-5-(methylene)pyrimidines are converted to tetrahydropyrimidin-5(4H)-ones by ozonlysis of the exo-methylene substituent.
  • these precursors are converted to novel 5,5-bis(difluoramino)hexahydropyrimidines and other geminal-bis(difluoramino)alkylene derivatives by difluoramination.
  • Z 1 is selected from the group consisting of halosulfonyl, polyhaloalkanesulfonyl, polyhaloarenesulfonyl, a regioisomer of fluoroarenesulfonyl, polyhaloarenesulfonyl, a regioisomer of cyanoarenesulfonyl, polycyanoarenesulfonyl, a regioisomer of nitroarenesulfonyl, and polynitroarenesulfonyl.
  • the regioisomer of fluoroarenesulfonyl is selected from the group consisting of 2-, 3- and 4-fluoro-substituted arenesulfonyl
  • the regioisomer of cyanoarenesulfonyl is selected from the group consisting of 2-, 3- and 4-cyano-substituted arenesulfonyl
  • the regioisomer of nitroarenesulfonyl is selected from the group consisting of 2-, 3- and 4-nitro-substituted arenesulfonyl.
  • R 2 is selected from the group consisting of hydrogen, C 1 -C 2 alkyl, protected hydroxymethyl and 1,2 ethanediyl.
  • reaction may also be accomplished using a carbonyl, rather than the R 2 groups illustrated above. That general path is illustrated as follows:
  • Z 1 is selected from the group consisting of halosulfonyl, polyhaloalkanesulfonyl, polyhaloarenesulfonyl, a regioisomer of fluoroarenesulfonyl, polyhaloarenesulfonyl, a regioisomer of cyanoarenesulfonyl, polycyanoarenesulfonyl, a regioisomer of nitroarenesulfonyl, and polynitroarenesulfonyl.
  • the regioisomer of fluoroarenesulfonyl is selected from the group consisting of 2-, 3- and 4-fluoro-substituted arenesulfonyl
  • the regioisomer of cyanoarenesulfonyl is selected from the group consisting of 2-, 3- and 4-cyano-substituted arenesulfonyl
  • the regioisomer of nitroarenesulfonyl is selected from the group consisting of 2-, 3- and 4-nitro-substituted arenesulfonyl.
  • Tetrahydropyrimidin-5(4H)-ones suitable for conversion to 5,5-bis(difluoramino)hexahydropyrimidines are substituted on the nitrogens (positions 1 and 3) by electron-withdrawing sulfonyl substituents.
  • the particular sulfonyl substituents are chosen from a specific group that imparts lower basicity to the nitrogens than to the oxygen in the tetrahydropyrimidin-5(4H)-ones. Therefore, the substitituent causes the nitrogens to have acid dissociation constants (pK a ) of the (protonated) conjugate acid forms of the nitrogen sites to be less than that of the ketones, typically about ⁇ 7.
  • the sulfonyl substituents may include alkanesulfonyl, halosulfonyl, or arenesulfonyl substituents, but the arenesulfonyl must have electron-withdrawing subsitituents on the phenyl rings.
  • the nitro group (NO 2 ) is a suitable electron-withdrawing subsitituent. Any single or multiple electron-withdrawing subsitituent(s) that collectively lower(s) the basicity of the arenesulfonyl-protected nitrogens below that of the oxygen in corresponding tetrahydropyrimidin-5(4H)-ones is (are) suitable.
  • alkanesulfonyl protecting groups may be electronegatively substituted to impart the same property on the protected nitrogens.
  • the sulfonyl substituent must have an inductive substituent constant ( ⁇ I or F) of a value greater than that of unsubstituted benzenesulfonyl, approximately 0.58.
  • ⁇ I or F inductive substituent constant
  • the geminal-bis(difluoramino)alkylene derivatives must be susceptible to nitrolysis to form N-protected nitramines (i.e. nitramides) and the intermediate nitramides must be susceptible to deprotection to form desired nitramine intermediates. Those intermediates then undergo cyclization by reaction with aldehydes or other alkylating reagents to form difluoramino-substituted heterocyclic nitramines.
  • 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine intermediate is reacted with an electrophile or alkylating reagent, such as aldehyde, alkylene dihalide, aldehyde equivalent or alkylene di(pseudohalide), to undergo cyclization to a desired difluoramino-substituted heterocyclic nitramine.
  • an electrophile or alkylating reagent such as aldehyde, alkylene dihalide, aldehyde equivalent or alkylene di(pseudohalide
  • a cyclic 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine is the same as a generic 5,5-bis(difluoramino)hexahydro-1,3-dinitropyrimidine when the cyclization is effected by a group containing only a single-carbon linkage between the two nitrogens (positions 1 and 3). This linkage may have additional substituents, but the pyrimidine linkage contains N—C—N atoms directly bonded.
  • the process of making RNFX consists of nitrolyzing the cyclic 2,2-bis(difluoramino)-N,N′-disulfonyl-1,3-propanediamine with nitric acid or other nitronium source to prepare a 2,2-bis(difluoramino)-N,N′-dinitro-N,N′-disulfonyl-1,3-propanediamine.
  • This nitrolysis may proceed via a 2,2-bis(difluoramino)-N-nitro-1,3-propanediamine intermediate, if a chemical linkage bridging the precursor's sulfonamide nitrogens is retained by one of the nitrogens upon nitrolysis.
  • the resulting deprotected nitramine, 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine, is then reacted with a difunctional electrophile suitable for cyclizing the bisnitramine.
  • electrophiles include aldehydes, dihaloalkanes, alkyl pseudohalides, other typical alkylating reagents, acylating reagents, and sulfonating reagents.
  • the use of formaldehyde as the cyclizing reagent produces the simple hexahydropyrimidine product (RNFX).
  • electronegatively substituted pyrimidines include those protected on nitrogen by chlorosulfonyl; fluorosulfonyl; cyanosulfonyl; polyhaloalkanesulfonyls, such as difluoromethanesulfonyl, trifluoromethanesulfonyl, and all perfluoroalkanesulfonyls; arenesulfonyls appropriately substituted such that collective effects of substituents on the arene impart the desired electronegativity on the arenesulfonyl, including, but not limited to, nitrobenzenesulfonyl (all isomers) and all polynitrobenzenesulfonyls.
  • Arenesulfonyl substituents may be based on arenes other than benzene, including various aromatic heterocycles, such as azines. Individual substituents on the arenesulfonyl of electronegativity comparable to or greater than that of nitro impart suitable electronegativity to the sulfonyl subsitituents to make suitable pyrimidine intermediates. The collective effect of multiple electronegative substituents of electronegativity less than that of nitro would also impart, collectively, the same necessary property of lowered basicity; examples include polyhaloarenesulfonyl and polycyanoarenesulfonyl protecting groups; other examples are apparent from compilations of quantitative inductive effects, such as Hansch et al. (op. cit.).
  • N-alkyl-N-nitrosulfonamides Based on the known general susceptibility of N-alkyl-N-nitrosulfonamides to nucleophilic N-desulfonation, it would be apparent that a variety of other N-sulfonyl subsituents are suitable for the present process of preparing 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine and subsequent cyclized derivatives, including alkanesulfonyl, arenesulfonyl (including heteroarenesulfonyl), and halosulfonyl protecting groups.
  • a cyclic 2,2-bis(difluoramino)-N,N′-disulfonyl-1,3-propanediamine precursor [specifically, 5,5-bis(difluoramino)hexahydro-1,3-bis(4-nitrobenzenesulfonyl)pyrimidine] contained methylene (CH 2 ) as a bridging link between sulfonamide nitrogens of the reactant; the methylene bridge was susceptible to nitrolysis to an N-nitratomethyl substituent which was also nitrolyzed, forming an N-nitrosulfonamide.
  • CH 2 methylene
  • the class of feasible examples thus includes perhydro-2,2′-bipyrimidines and a variety of other bicyclic systems linked to the 2-position of the reactant 5,5-bis(difluoramino)hexahydro-1,3-disulfonylpyrimidine.
  • 1,3-propanediamines are known to condense with glyoxal to form perhydro-2,2′-bipyrimidines; 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine thus forms 5,5,5′,5′-tetrakis (difluoramino)perhydro-1,1′,3,3′-tetranitro-2,2′-bipyrimidine with glyoxal.
  • reaction mixture was filtered and the solid was washed with 100 mL of toluene, then with 100 mL of water. The solid was dried at room temperature under reduced pressure to give 4.4 g (95%) of crude product, hexahydro-1,3-bis(4-nitrobenzenesulfonyl)-5-pyrimidinol.
  • a stream of ozone in oxygen was bubbled into a solution of hexahydro-5-(methylene)-1,3-bis(4-nitrobenzenesulfonyl)pyrimidine (0.6 g, 1.3 mmol) in 150 mL acetone at ⁇ 78° C. (dry ice-acetone bath) until a blue color persisted for 5 minutes.
  • the reaction was stirred for 15 minutes under a nitrogen atmosphere. Next, 2.0 mL of dimethyl sulfide was added.
  • the mixture was basified with aqueous sodium carbonate to pH 6 and then extracted with dichloromethane.
  • the solvent was removed from this extract by rotary evaporation and the residue was redissolved in chloroform and chromatographed on silica gel, eluting successively with chloroform (two fractions) and dichloromethane (three fractions).
  • Fraction #2 eluted by chloroform, contained a mixture of 2,2-bis(difluoramino)-N,N′-bis(difluoraminomethyl)-N,N′-(4-nitrobenzenesulfonyl)-1,3-propanediamine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Calculated performance improvements are expected from a particularly new class of compounds, geminal-bis(difluoramino)-substituted heterocyclic nitramines, when formulated into explosives and propellants. This invention involves novel and nonintuitive methods for the preparation of certain derivatives of 2,2-bis(difluoramino)-N-nitro-1,3-propanediamine which are suitable precursors leading to 5,5-bis(difluoramino)hexahydro-1,3-dinitropyrimidine (RNFX). The invention also involves novel and nonintuitive methods for the preparation of RNFX, a specific member of a general class of compounds with the substructure 2,2-bis(difluoramino)-N-nitro-1,3-propanediamine. RNFX is produced by the use of key intermediates, including tetrahydropyrimidin-5(4H)-ones, which allow formation of the target structural subcomponent, 2,2-bis(difluoramino)-N-nitro-1,3-propanediamine, and a more specific substructure of 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine. In addition, this invention involves 5,5-bis(difluoramino)hexahydropyrimidine derivatives, related geminal-bis(difluoramino)alkylene derivatives, and novel precursors to these new derivatives, by the use of certain novel key intermediates.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is being filed as a Divisional Application in accordance with 37 C.F.R. 1.53(b). The Parent Application of this Divisional Application is application Ser. No. 09/505,127 filed Feb. 16, 2000.[0001]
  • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention [0002]
  • This invention involves the calculated performance improvements expected from a particularly new class of compounds, geminal-bis(difluoramino)-substituted heterocyclic nitramines, when formulated into explosives and propellants. Further, this invention involves 5,5-bis(difluoramino)hexahydropyrimidine derivatives, related geminal-bis(difluoramino)alkylene derivatives, and novel precursors to these new derivatives, by the use of certain key intermediates which allow formation of this target structural subcomponent. [0003]
  • 2. Description of the Related Art [0004]
  • The calculated performance improvements expected from geminal-bis(difluoramino)-substituted heterocyclic nitramines when formulated into explosives and propellants has been reported. [Miller, [0005] Materials Research Society Proceedings 1996, 418, 3] One example of a highly desirable structure, described by Miller, is a derivative of 5,5-bis(difluoramino)hexahydro-1,3-dinitropyrimidine which has the following formula:
    Figure US20020007063A1-20020117-C00001
  • wherein R[0006] 2 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl. The highly desirable structure, given the acronym RNFX by Miller, exists when R2 is hydrogen.
  • Methodology for preparing a geminal-bis(difluoramino)-substituted nitrogenous heterocycle has been reported by Chapman et al. [[0007] Journal of Organic Chemistry 1998, 63, 1566], who describe the preparation of 3,3,7,7-tetrakis(difluoramino)octahydro-1,5-bis(4-nitrobenzenesulfonyl)-1,5-diazocine; this intermediate has been converted to the corresponding nitramine, 3,3,7,7-tetrakis(difluoramino)octahydro-1,5-dinitro-1,5-diazocine, given the acronym HNFX [Chapman et al, Journal of Organic Chemistry, 1999, 64, 960]. However the preparation of cyclic derivatives of 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine in which the nitramine components are linked with a single-carbon bridge, such as RNFX, has not been previously described.
  • SUMMARY OF THE INVENTION
  • This invention involves novel and nonintuitive methods for the preparation of certain derivatives of 2,2-bis(difluoramino)-N-nitro-1,3-propanediamine which are suitable precursors leading to RNFX. However, the synthesis of certain examples of this class of compounds is difficult and nonintuitive. The certain examples that are particularly synthetically difficult are molecules that incorporate the geminal-bis(difluoramino)alkylene [C(NF[0008] 2)2] component and the nitramine component [N—NO2] in close proximity, especially when separated by only a methylene (CH2) link in order to maintain a low fuel-to-oxidizer component ratio and concomitantly high oxygen balance in the product molecule. The invention also involves novel and nonintuitive methods for the preparation of RNFX, a specific member of a general class of compounds with the substructure 2,2-bis(difluoramino)-N-nitro-1,3-propanediamine. RNFX is produced by the use of key intermediates which allow formation of the target structural subcomponents, 2,2-bis(difluoramino)-N-nitro-1,3-propanediamine and a more specific substructure of 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine, which has the following structure:
    Figure US20020007063A1-20020117-C00002
  • Also, this invention comprises certain unprecedented nitramides and nitramines suitable for conversion to RNFX and a variety of other difluoramino-substituted heterocyclic nitramines. An important aspect of the present invention is the substitution on hetero cyclic precursors' nitrogen atoms and intermediate nitramides' nitrogen atoms. The nitrogen atoms of heterocyclic precursors (such as pyrimidines) must be suitably substituted, or “protected,” during the process of difluoramination to allow this process to proceed to geminal-bis(difluoramino)alkylene derivatives. Without suitable protection of proximate multiple nitrogens, especially those separated from reacting carbonyl sites by a short bridge, such as methylene, the process of difluoramination of ketone intermediates does not proceed to geminal-bis(difluoramino)alkylene derivatives. The result is mono(difluoramino)alkylene derivatives or no reaction at all. [0009]
  • An object of this invention is to create a novel explosive and propellant involving geminal-bis(difluoramino)-substituted heterocyclic nitramines. [0010]
  • Another object of this invention is to create a novel method of producing 5,5-bis(difluoramino)hexahydro-1,3-dinitropyrimidine using electronegatively substituted pyrimidines and other novel intermediates leading to RNFX. [0011]
  • BRIEF DESCRIPTION DRAWINGS
  • Not Applicable. [0012]
  • DETAILED DESCRIPTION OF THE INVENTION
  • The collection of pyrimidine intermediates disclosed in this invention which are suitable for eventual conversion to RNFX must allow formation of a tetrahydropyrimidin-5(4H)-one having the following structure: [0013]
    Figure US20020007063A1-20020117-C00003
  • wherein Z[0014] 1 is selected from the group consisting of halosulfonyl, polyhaloalkanesulfonyl, polyhaloarenesulfonyl, a regioisomer of fluoroarenesulfonyl, polyhaloarenesulfonyl, a regioisomer of cyanoarenesulfonyl, polycyanoarenesulfonyl, a regioisomer of nitroarenesulfonyl, and polynitroarenesulfonyl. Further, the regioisomer of fluoroarenesulfonyl is selected from the group consisting of 2-, 3- and 4-fluoro-substituted arenesulfonyl, the regioisomer of cyanoarenesulfonyl is selected from the group consisting of 2-, 3- and 4-cyano-substituted arenesulfonyl and the regioisomer of nitroarenesulfonyl is selected from the group consisting of 2-, 3- and 4-nitro-substituted arenesulfonyl.
  • In the invention, a tetrahydropyrimidin-5(4H)-one is a necessary precursor to a 5,5-bis(difluoramino)hexahydropyrimidine, based on the known conversion of ketone carbonyl groups by reaction with difluoramine or difluorosulfamic acid in the presence of a strong acid. The nitrogen-protecting groups chosen for the new pyrimidine intermediates and precursors are certain sulfonyl substituents. The particular sulfonyl substituents are chosen from a group that favorably affects the basicity of the pyrimidine nitrogens to make them less basic than the oxygen sites in the pyrimidine intermediates, in order to allow difluoramination of the carbonyl oxygens to proceed to geminal-bis(difluoramino)alkylene derivatives. [0015]
  • Suitable intermediates leading to tetrahydropyrimidin-5(4H)-ones include hexahydro-5-pyrimidinols (including their oxygen-protected derivatives) and hexahydro-5-(methylene)pyrimidines. These novel N-sulfonylpyrimidine derivatives include hexahydro-5-pyrimidinols having the structure: [0016]
    Figure US20020007063A1-20020117-C00004
  • wherein Z[0017] 1 is selected from the group consisting of halosulfonyl, polyhaloalkanesulfonyl, polyhaloarenesulfonyl, a regioisomer of fluoroarenesulfonyl, polyhaloarenesulfonyl, a regioisomer of cyanoarenesulfonyl, polycyanoarenesulfonyl, a regioisomer of nitroarenesulfonyl, and polynitroarenesulfonyl. Further, the regioisomer of fluoroarenesulfonyl is selected from the group consisting of 2-, 3- and 4-fluoro-substituted arenesulfonyl, the regioisomer of cyanoarenesulfonyl is selected from the group consisting of 2-, 3- and 4-cyano-substituted arenesulfonyl and the regioisomer of nitroarenesulfonyl is selected from the group consisting of 2-, 3- and 4-nitro-substituted arenesulfonyl.; and
  • wherein R[0018] 1 is selected from the group consisting of hydrogen and an alcohol-protecting group.
  • The novel N-sulfonylpyrimidine derivatives also include hexahydro-5-(methylene)pyrimidines having the following structure: [0019]
    Figure US20020007063A1-20020117-C00005
  • wherein Z[0020] 1 is selected from the group consisting of halosulfonyl, polyhaloalkanesulfonyl, polyhaloarenesulfonyl, a regioisomer of fluoroarenesulfonyl, polyhaloarenesulfonyl, a regioisomer of cyanoarenesulfonyl, polycyanoarenesulfonyl, a regioisomer of nitroarenesulfonyl, and polynitroarenesulfonyl. Further, the regioisomer of fluoroarenesulfonyl is selected from the group consisting of 2-, 3- and 4-fluoro-substituted arenesulfonyl, the regioisomer of cyanoarenesulfonyl is selected from the group consisting of 2-, 3- and 4-cyano-substituted arenesulfonyl and the regioisomer of nitroarenesulfonyl is selected from the group consisting of 2-, 3- and 4-nitro-substituted arenesulfonyl.
  • In the preferred embodiment, a hexahydro-5-(methylene)pyrimidine is utilized as the intermediate leading to a tetrahydropyrimidin-5(4H)-one. In the present invention, the production of hexahydro-5-(methylene)pyrimidines is accomplished as follows: [0021]
    Figure US20020007063A1-20020117-C00006
  • wherein Z[0022] 1 is selected from the group consisting of halosulfonyl, polyhaloalkanesulfonyl, polyhaloarenesulfonyl, a regioisomer of cyanoarenesulfonyl, polycyanoarenesulfonyl, a regioisomer of nitroarenesulfonyl, and polynitroarenesulfonyl. Further, the regioisomer of fluoroarenesulfonyl is selected from the group consisting of 2-, 3- and 4-fluoro-substituted arenesulfonyl, the regioisomer of cyanoarenesulfonyl is selected from the group consisting of 2-, 3- and 4-cyano-substituted arenesulfonyl and the regioisomer of nitroarenesulfonyl is selected from the group consisting of 2-,3- and 4-nitro-substituted arenesulfonyl.
  • Hexahydro-5-pyrimidinols and hexahydro-5-(methylene)pyrimidines are suitable intermediates that can be converted to tetrahydropyrimidin-5(4H)-one precursors. For example, hexahydro-5-(methylene)pyrimidines are converted to tetrahydropyrimidin-5(4H)-ones by ozonlysis of the exo-methylene substituent. Next, these precursors are converted to novel 5,5-bis(difluoramino)hexahydropyrimidines and other geminal-bis(difluoramino)alkylene derivatives by difluoramination. [0023]
  • In the preferred embodiment of the invention, the general path of the reaction, after the formation of a tetrahydropyrimidin-5(4H)-one, is illustrated as follows: [0024]
    Figure US20020007063A1-20020117-C00007
  • wherein Z[0025] 1 is selected from the group consisting of halosulfonyl, polyhaloalkanesulfonyl, polyhaloarenesulfonyl, a regioisomer of fluoroarenesulfonyl, polyhaloarenesulfonyl, a regioisomer of cyanoarenesulfonyl, polycyanoarenesulfonyl, a regioisomer of nitroarenesulfonyl, and polynitroarenesulfonyl. Further, the regioisomer of fluoroarenesulfonyl is selected from the group consisting of 2-, 3- and 4-fluoro-substituted arenesulfonyl, the regioisomer of cyanoarenesulfonyl is selected from the group consisting of 2-, 3- and 4-cyano-substituted arenesulfonyl and the regioisomer of nitroarenesulfonyl is selected from the group consisting of 2-, 3- and 4-nitro-substituted arenesulfonyl.; and
  • wherein R[0026] 2 is selected from the group consisting of hydrogen, C1-C2 alkyl, protected hydroxymethyl and 1,2 ethanediyl.
  • In another embodiment of the invention, the reaction may also be accomplished using a carbonyl, rather than the R[0027] 2 groups illustrated above. That general path is illustrated as follows:
    Figure US20020007063A1-20020117-C00008
  • wherein Z[0028] 1 is selected from the group consisting of halosulfonyl, polyhaloalkanesulfonyl, polyhaloarenesulfonyl, a regioisomer of fluoroarenesulfonyl, polyhaloarenesulfonyl, a regioisomer of cyanoarenesulfonyl, polycyanoarenesulfonyl, a regioisomer of nitroarenesulfonyl, and polynitroarenesulfonyl. Further, the regioisomer of fluoroarenesulfonyl is selected from the group consisting of 2-, 3- and 4-fluoro-substituted arenesulfonyl, the regioisomer of cyanoarenesulfonyl is selected from the group consisting of 2-, 3- and 4-cyano-substituted arenesulfonyl and the regioisomer of nitroarenesulfonyl is selected from the group consisting of 2-, 3- and 4-nitro-substituted arenesulfonyl.
  • Tetrahydropyrimidin-5(4H)-ones suitable for conversion to 5,5-bis(difluoramino)hexahydropyrimidines are substituted on the nitrogens (positions 1 and 3) by electron-withdrawing sulfonyl substituents. The particular sulfonyl substituents are chosen from a specific group that imparts lower basicity to the nitrogens than to the oxygen in the tetrahydropyrimidin-5(4H)-ones. Therefore, the substitituent causes the nitrogens to have acid dissociation constants (pK[0029] a) of the (protonated) conjugate acid forms of the nitrogen sites to be less than that of the ketones, typically about −7.
  • The sulfonyl substituents may include alkanesulfonyl, halosulfonyl, or arenesulfonyl substituents, but the arenesulfonyl must have electron-withdrawing subsitituents on the phenyl rings. For example, the nitro group (NO[0030] 2) is a suitable electron-withdrawing subsitituent. Any single or multiple electron-withdrawing subsitituent(s) that collectively lower(s) the basicity of the arenesulfonyl-protected nitrogens below that of the oxygen in corresponding tetrahydropyrimidin-5(4H)-ones is (are) suitable. Similarly, alkanesulfonyl protecting groups may be electronegatively substituted to impart the same property on the protected nitrogens. In general, the sulfonyl substituent must have an inductive substituent constant (σI or F) of a value greater than that of unsubstituted benzenesulfonyl, approximately 0.58. Such electronegatively substituted pyrimidines are unprecedented.
  • The geminal-bis(difluoramino)alkylene derivatives must be susceptible to nitrolysis to form N-protected nitramines (i.e. nitramides) and the intermediate nitramides must be susceptible to deprotection to form desired nitramine intermediates. Those intermediates then undergo cyclization by reaction with aldehydes or other alkylating reagents to form difluoramino-substituted heterocyclic nitramines. [0031]
  • In the final step of the process, 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine intermediate is reacted with an electrophile or alkylating reagent, such as aldehyde, alkylene dihalide, aldehyde equivalent or alkylene di(pseudohalide), to undergo cyclization to a desired difluoramino-substituted heterocyclic nitramine. A cyclic 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine is the same as a generic 5,5-bis(difluoramino)hexahydro-1,3-dinitropyrimidine when the cyclization is effected by a group containing only a single-carbon linkage between the two nitrogens (positions 1 and 3). This linkage may have additional substituents, but the pyrimidine linkage contains N—C—N atoms directly bonded. [0032]
  • The process of making RNFX consists of nitrolyzing the cyclic 2,2-bis(difluoramino)-N,N′-disulfonyl-1,3-propanediamine with nitric acid or other nitronium source to prepare a 2,2-bis(difluoramino)-N,N′-dinitro-N,N′-disulfonyl-1,3-propanediamine. This nitrolysis may proceed via a 2,2-bis(difluoramino)-N-nitro-1,3-propanediamine intermediate, if a chemical linkage bridging the precursor's sulfonamide nitrogens is retained by one of the nitrogens upon nitrolysis. The resulting 2,2-bis(difluoramino)-N,N′-dinitro-N,N′-disulfonyl-1,3-propanediamine is then subjected to nucleophilic displacement of the sulfonyl protecting group. In 2,2-bis(difluoramino)propanamine derivatives, this deprotection is relatively facile, and appropriate nucleophiles include a wide variety of oxygen, nitrogen and other heteroatom derivatives, examples of which include water, alcohols and amines. The resulting deprotected nitramine, 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine, is then reacted with a difunctional electrophile suitable for cyclizing the bisnitramine. A variety of electrophiles are suitable for this purpose, including aldehydes, dihaloalkanes, alkyl pseudohalides, other typical alkylating reagents, acylating reagents, and sulfonating reagents. The use of formaldehyde as the cyclizing reagent produces the simple hexahydropyrimidine product (RNFX). [0033]
  • In the successful examples cited below, 4-nitrobenzenesulfonyl was used as a role model nitrogen-protecting sulfonyl group to prepare electronegatively substituted pyrimidines as intermediates and precursors leading to geminal-bis(difluoramino)alkylene derivatives. A wide variety of other heretofore unknown pyrimidine derivatives suitable for conversion, successively, to tetrapyrimidin-5-(4H)-ones and then to geminal-bis(difluoramino)alkylene derivatives becomes apparent from a review of known electron-withdrawing properties of sulfonyl substituents, such as reviewed by Hansch et al., [0034] Chemical Reviews 1991, 91, 165; these require that inductive substituent constants, σI or F, are greater than approximately 0.58, the value known for unsubstituted benzenesulfonyl. Thus, other suitable electronegatively substituted pyrimidines include those protected on nitrogen by chlorosulfonyl; fluorosulfonyl; cyanosulfonyl; polyhaloalkanesulfonyls, such as difluoromethanesulfonyl, trifluoromethanesulfonyl, and all perfluoroalkanesulfonyls; arenesulfonyls appropriately substituted such that collective effects of substituents on the arene impart the desired electronegativity on the arenesulfonyl, including, but not limited to, nitrobenzenesulfonyl (all isomers) and all polynitrobenzenesulfonyls.
  • Arenesulfonyl substituents may be based on arenes other than benzene, including various aromatic heterocycles, such as azines. Individual substituents on the arenesulfonyl of electronegativity comparable to or greater than that of nitro impart suitable electronegativity to the sulfonyl subsitituents to make suitable pyrimidine intermediates. The collective effect of multiple electronegative substituents of electronegativity less than that of nitro would also impart, collectively, the same necessary property of lowered basicity; examples include polyhaloarenesulfonyl and polycyanoarenesulfonyl protecting groups; other examples are apparent from compilations of quantitative inductive effects, such as Hansch et al. (op. cit.). [0035]
  • In the successful examples cited below, 4-nitrobenzenesulfonyl was used as a model nitrogen-protecting sulfonyl group to prepare 2,2-bis(difluoramino)-N,N′-dinitro-N,N′-bis(4-nitrobenzenesulfonyl)-1,3-propanediamine intermediates susceptible to nucleophilic N-desulfonation and subsequent cyclization by appropriate electrophiles. Based on the known general susceptibility of N-alkyl-N-nitrosulfonamides to nucleophilic N-desulfonation, it would be apparent that a variety of other N-sulfonyl subsituents are suitable for the present process of preparing 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine and subsequent cyclized derivatives, including alkanesulfonyl, arenesulfonyl (including heteroarenesulfonyl), and halosulfonyl protecting groups. [0036]
  • In the successful examples cited below, a cyclic 2,2-bis(difluoramino)-N,N′-disulfonyl-1,3-propanediamine precursor [specifically, 5,5-bis(difluoramino)hexahydro-1,3-bis(4-nitrobenzenesulfonyl)pyrimidine] contained methylene (CH[0037] 2) as a bridging link between sulfonamide nitrogens of the reactant; the methylene bridge was susceptible to nitrolysis to an N-nitratomethyl substituent which was also nitrolyzed, forming an N-nitrosulfonamide. Based on the known susceptibility to nitrolysis of “substituted methylene” linkages bridging heterocyclic nitrogens, other 5,5-bis(difluoramino)hexahydro-1,3-disulfonylpyrimidines substituted in the 2-position are also suitable reactants for the nitrolysis step generating 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine derivatives. The 2-position substituents that remain feasible within the present process include a wide variety of alkyl, aryl (including heteroaryl) and cyclic alkyl (including heterocyclic alkyl) substituents. The class of feasible examples thus includes perhydro-2,2′-bipyrimidines and a variety of other bicyclic systems linked to the 2-position of the reactant 5,5-bis(difluoramino)hexahydro-1,3-disulfonylpyrimidine.
  • In the successful examples cited below, a formaldehyde equivalent generated in situ during nitrolysis of an N-nitratomethyl substituent was used to recyclize 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine to form RNFX. Based on the known general reactivity of primary nitramines with aldehydes (under acid catalyzed conditions) and other electrophiles, the present process is extensible to the formation of other cyclic 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine derivatives via cyclization with alternative electrophiles. For example, 1,3-propanediamines are known to condense with glyoxal to form perhydro-2,2′-bipyrimidines; 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine thus forms 5,5,5′,5′-tetrakis (difluoramino)perhydro-1,1′,3,3′-tetranitro-2,2′-bipyrimidine with glyoxal. [0038]
  • Although the description above contains many specificities, these should not be construed as limiting the scope of the invention but as merely providing an illustration of the presently preferred embodiment of the invention. Thus the scope of this invention should be determined by the appended claims and their legal equivalents.[0039]
  • EXAMPLES Example 1
  • Preparation of hexahydro-1,3-bis(4-nitrobenzenesulfonyl)-5-pyrimidinol [0040]
  • A 37% aqueous solution of formaldehyde (1.34 mL) was added dropwise to a stirred solution of 1,3-diamino-2-hydroxypropane (Aldrich Chemical Co., 95% purity, 1.5 g, 17 mmol) in 8 mL of water over 30 minutes at room temperature. After stirring at room temperature for 3 days, the solvent was removed via distillation to give a light yellow solid, hexahydro-5-pyrimidinol. [0041]
  • A solution of hexahydro-5-pyrimidinol (1.0 g, 9.8 mmol) and sodium carbonate (1.04 g, 9.8 mmol) in 10 mL of water in a 250 mL round bottom flask was stirred with a magnetic stir bar for 10 minutes. A solution of 4-nitrobenzenesulfonyl chloride (4.4 g, 19.8 mmol) in 10 mL of toluene was added dropwise over a period of 30 minutes. The reaction mixture formed a white suspended solid. A mixture of 100 mL of water and 20 mL of toluene was added to the reaction mixture and stirred overnight. The reaction mixture was filtered and the solid was washed with 100 mL of toluene, then with 100 mL of water. The solid was dried at room temperature under reduced pressure to give 4.4 g (95%) of crude product, hexahydro-1,3-bis(4-nitrobenzenesulfonyl)-5-pyrimidinol. [[0042] 1H NMR (DMSO-d6): δ 2.29 (s, 1H), 2.84, 3.47 {AB q of d, J=12.4(3.8) Hz, 12.4(7.9) Hz, 4H}, 3.30 (m, 1H), 4.46,5.07 (AB q, J=12.5 Hz, 2H), 5.31 (s, 1H), 8.11,8.41 (AB q, J=8.7 Hz, 8H); 13C NMR (DMSO-d6): δ 50.0, 59.8, 60.6, 124.6, 128.9, 143.3, 150.1].
  • Example 2
  • Preparation of hexahydro-5-(methylene)-1,3-bis(4-nitrobenzenesulfonyl)pyrimidine [0043]
  • A suspended mixture of 4-nitrobenzenesulfonamide (2.0 g, 9.9 mmol) and potassium carbonate (0.68 g, 4.9 mmol) in 100 mL water was stirred and heated at 70° C. until the reaction mixture turned clear. Aqueous 37% formaldehyde (0.2 mL, 4.9 mmol) was added and the mixture heated at 70° C. for 3 days. The reaction mixture was concentrated by removal of water via rotary evaporation at reduced pressure. The reaction mixture was neutralized to pH 7 with hydrochloric acid. The resulting solid was filtered and washed with water to give 0.7 g (18%) of methylenebis(4-nitrobenzenesulfonamide) [[0044] 1H NMR (acetone-d6): δ 2.82 (s, 2H), 4.86 (m, 2H), 8.07, 8.35 (AB q, J=8.9 Hz, 8H); 13C NMR (acetone-d6) δ 53.0, 125.2, 129.1, 148.4, 151.0]. The yield of this reaction ranged from 10-30%. A mixture of methylenebis(4-nitrobenzenesulfonamide) (1.0 g, 2.4 mmol), potassium carbonate (0.66 g, 4.8 mmol), and 3-chloro-2-(chloromethyl)-1-propene (0.3 g, 2.4 mmol) in 150 mL of acetonitrile was stirred and heated at reflux under a nitrogen atmosphere for 20 h. The solvent was removed under reduced pressure, and the remaining solid was chromatographed (silica gel-ethyl acetate) to give 0.84 g (75%) of solid, hexahydro-5-(methylene)-1,3-bis(4-nitrobenzenesulfonyl)pyrimidine [1H NMR (acetone-d6): δ 3.90 (s, 4H), 4.95 (m, 2H), 5.00 (s, 2H), 8.18, 8.44 (AB q oft, J=9.0(2.2) Hz, 8H); 13C NMR (acetone-d6): δ 51.0, 61.7, 116.2, 125.3, 130.6, 133.6, 144.6, 151.6].
  • Example 3
  • Preparation of tetrahydro-1,3-bis(4-nitrobenzenesulfonyl)pyrimidin-5(4H)-one [0045]
  • A stream of ozone in oxygen was bubbled into a solution of hexahydro-5-(methylene)-1,3-bis(4-nitrobenzenesulfonyl)pyrimidine (0.6 g, 1.3 mmol) in 150 mL acetone at −78° C. (dry ice-acetone bath) until a blue color persisted for 5 minutes. The reaction was stirred for 15 minutes under a nitrogen atmosphere. Next, 2.0 mL of dimethyl sulfide was added. After stirring for 10 minutes, the solvent was removed and the solid dried under reduced pressure to give 0.5 g (83%) of tetrahydro-1,3-bis(4-nitrobenzenesulfonyl)pyrimidin-5(4H)-one. [[0046] 1H NMR (acetone-d6): δ 3.95 (s, 4H), 5.25 (s, 2H), 8.20, 8.48 (AB q, J=9.0 Hz, 8H); 13C NMR (DMSO-d6): δ 53.8, 58.8, 124.8, 129.3, 141.9, 150.4, 196.2].
  • Example 4
  • Preparation of 2,2-bis(difluoramino)-N,N′-bis(difluoraminomethyl)-N,N′-(4-nitrobenzenesulfonyl)-1,3-propanediamine [0047]
  • Difluoramine (2.2 g, 41.5 mmol) was absorbed into a mixture of 3.0 mL fuming sulfuric acid (30% SO[0048] 3) plus 100 mL of trichlorofluoromethane in a temperature range of —15 to +5° C. Tetrahydro-1,3-bis(4-nitrobenzenesulfonyl)pyrimidin-5(4H)-one (0.255 g, 0.54 mmol) was added via a solid addition funnel with another 15 mL of trichlorofluoromethane to wash out the funnel. After 3 h stirring at −15° C., the reaction mixture was poured onto ice. The mixture was basified with aqueous sodium carbonate to pH 6 and then extracted with dichloromethane. The solvent was removed from this extract by rotary evaporation and the residue was redissolved in chloroform and chromatographed on silica gel, eluting successively with chloroform (two fractions) and dichloromethane (three fractions). Fraction #2, eluted by chloroform, contained a mixture of 2,2-bis(difluoramino)-N,N′-bis(difluoraminomethyl)-N,N′-(4-nitrobenzenesulfonyl)-1,3-propanediamine [1H NMR (chloroform-d): δ 4.39 (s), 5.09 (t), 8.12, 8.44 (AB q, J=8.9 Hz); 19F NMR (chloroform-d): δ 30.59 (s), 44.86 (t, J=22.9 Hz)] and N,N-bis(difluoraminomethyl)-4-nitrobenzenesulfonamide [1H NMR (chloroform-d): δ 5.03 (t, J=22.6 Hz, 4H), 8.09, 8.42 (AB q, J=8.9 Hz, 8H); 19F NMR (chloroform-d): δ 43.53 (t, J=22.4 Hz)].
  • Example 5
  • Preparation of 5,5-bis(difluoramino)hexahydro-1,3-bis(4-nitrobenzenesulfonyl)pyrimidine and 5,5-bis(difluoramino)-1-(difluoraminomethyl)hexahydro-3-(4-nitrobenzenesulfonyl)pyrimidine [0049]
  • The same reaction as described in Example 4 is performed. Elution of chromatography Fraction #3 with dichloromethane produced a mixture containing predominantly 5,5-bis(difluoramino)hexahydro-1,3-bis(4-nitrobenzenesulfonyl) pyrimidine [[0050] 1H NMR (dichloromethane-d2-chloroform-d): δ 3.98 (s, 4H), 4.98 (s, 2H), 8.07, 8.42 (AB q, J=9.0 Hz, 8H); 13C NMR (dichloromethane-d2-chloroform-d): δ 44.3 (m, J=9.0 Hz), 60.4, 89.7 (m), 125.3, 129.5, 144.0, 151.4; 19F NMR (dichloromethane-d2-chloroform-d): δ 27.27] plus minor amounts of 5,5-bis(difluoramino)-1-(difluoraminomethyl)hexahydro-3-(4-nitrobenzenesulfonyl)pyrimidine [19F NMR (dichloromethane-d2-chloroform-d): δ 21.65, 28.15 (AB q, J=610 Hz, 4 F), 45.38 (t, J=20.8 Hz, 2 F)], N-(difluoraminomethyl)-4-nitrobenzenesulfonamide [19F NMR (dichloromethane-d2-chloroform-d): δ 39.86 (td, J=22.6, 7.6 Hz)] and N,N-bis(difluoraminomethyl)-4-nitrobenzenesulfonamide.
  • Example 6
  • Preparation of 5,5-bis(difluoramino)hexahydro-1,3-bis(4-nitrobenzenesulfonyl)pyrimidine [0051]
  • The same reaction as in Example 4 is performed. Elution of chromatography Fraction #4 with dichloromethane produced effectively pure 5,5-bis(difluoramino)hexahydro-1,3-bis(4-nitrobenzenesulfonyl) pyrimidine. [0052]
  • Example 7
  • Preparation of 2,2-bis(difluoramino)-N-(nitratomethyl)-N-nitro-N,N′-bis(4-nitrobenzenesulfonyl)-1,3-propanediamine [0053]
  • 5,5-Bis(difluoramino)hexahydro-1,3-bis(4-nitrobenzenesulfonyl)pyrimidine is dissolved in a large excess of ca. 98% nitric acid. Nitrolysis of the methylene bridge in this reactant is conveniently followed by [0054] 19F NMR spectrometry. Nitrolysis initially produces 2,2-bis(difluoramino)-N-(nitratomethyl)-N′-nitro-N,N′-bis(4-nitrobenzenesulfonyl)-1,3-propanediamine [1H NMR (HNO3): δ 4.53 (s), 5.09 (s), 5.88 (s), 8.42, 8.78 (AB q, J=9.0 Hz, 4H, N-aryl), 8.43, 8.70 (AB q, J=9.0 Hz, 4H, N′-aryl); 13C NMR (HNO3): δ 44.2, 45.8, 60.6, 90.8, 125.6, 128.6, 131.3, 143.1, 146.6, 150.5, 151.6; 19F NMR (HNO3): δ 29.39].
  • Example 8
  • Preparation of 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine [0055]
  • Nitrolysis of the intermediate formed in Example 7 replaces the N-nitratomethyl substitituent with N-nitro. The reaction rates of the successive nitrolysis steps are expectedly influenced by the concentration of reactants—the sulfonamides and nitric acid. With a proper proportion of reactants, the next step of the sequence occurs spontaneously: 2,2-bis(difluoramino)-N,N′-dinitro-N,N′-bis(4-nitrobenzenesulfonyl)-1,3-propanediamine is adventitiously N-desulfonated by the water contained in the concentrated nitric acid, forming 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine, which does not accumulate but combines spontaneously with the formaldehyde equivalent generated in this nitrolysis, as described in Example 9. [0056]
  • Example 9
  • Preparation of 5,5-bis(difluoramino)hexahydro-1,3-dinitropyrimidine (RNFX) [0057]
  • Under the conditions of nitrolysis of 2,2-bis(difluoramino)-N-(nitratomethyl)-N-nitro-N,N′-bis(4-nitrobenzenesulfonyl)-1,3-propanediamine in ca. 98% nitric acid, the liberated formaldehyde equivalent becomes available for cyclization of the N-desulfonated bis(primary nitramine), 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine. The cyclization occurred spontaneously at room temperature, consuming the 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine intermediate and forming 5,5-bis(difluoramino)hexahydro-1,3-dinitropyrimidine (RNFX) [[0058] 1H NMR (CD3CN): δ 4.85 (s, 4H), 6.06 (s, 2H); 1H NMR (acetone-d6): δ 5.07 (s, 4H), 6.31 (s, 2H); 13C NMR (CD3CN): δ 45.3 (m, J=6 Hz), 60.6 (s) (not all carbons detected due to low S/N); 19F NMR (CD3CN): δ 29.67; 19F NMR (acetone-d6): δ 29.31)].

Claims (17)

What is claimed is:
1. A method of preparing a cyclic 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine which comprises the steps of:
reacting with an electrophile, a 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine having a formula:
Figure US20020007063A1-20020117-C00009
 and
producing a cyclic 2,2-bis(difluoramino)-N,N′-dinitro-1,3- propanediamine having a formula selected from the group consisting of:
Figure US20020007063A1-20020117-C00010
wherein R2is selected from the group consisting of hydrogen, alkyl, and substituted alkyl.
2. The method according to claim 1 wherein said electrophile is selected from the group consisting of aldehyde, aldehyde equivalent, alkylene dihalide, and alkylene di(pseudohalide).
3. The method according to claim 2 wherein said aldehyde is selected from the group consisting of formaldehyde, glyoxal, a nitrate ester of formaldehyde and a nitrate ester of glyoxal.
4. The method according to claim 1, wherein said reacting with an electrophile takes place at a temperature ranging from about −80° C. to about 120° C.
5. The method according to claim 1, further comprising the steps of:
reacting a generic 2,2-bis(difluoramino)-N-nitro-N,N′-disulfonyl-1,3-propanediamine with a nitronium source; and
producing said 2,2-bis(difluoramino)-N,N′-dinitro-1,3-propanediamine.
6. The method according to claim 5 wherein said nitronium source is selected from the group consisting of nitric acid, a nitronium salt, and a covalent nitryl derivative.
7. The method according to claim 5, wherein said reacting with a nitronium source takes place at a temperature ranging from about −80° C. to about 120° C.
8. The method according to claim 5, further comprising the steps of:
reacting with a nitronium source a 5,5-bis(difluoramino)hexahydro-1,3-disulfonylpyrimidine having a formula selected from the group consisting of:
Figure US20020007063A1-20020117-C00011
 and
recovering a 2,2-bis(difluoramino)-N-nitro-N,N′-disulfonyl-1,3-propanediamine having a formula selected from the group consisting of:
Figure US20020007063A1-20020117-C00012
wherein R2 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl; and
wherein Z1 is selected from the group consisting of halosulfonyl, polyhaloalkanesulfonyl, polyhaloarenesulfonyl, a regioisomer of fluoroarenesulfonyl, polyhaloarenesulfonyl, a regioisomer of cyanoarenesulfonyl, polycyanoarenesulfonyl, a regioisomer of nitroarenesulfonyl, and polynitroarenesulfonyl.
9. The method according to claim 8 wherein said nitronium source is selected from the group consisting of nitric acid, a nitronium salt, and a covalent nitryl derivative.
10. The method according to claim 8 wherein said 5,5-bis(difluoramino)hexahydro-1,3-disulfonylpyrimidine is a 2-substituted pyrimidine.
11. The method according to claim 8, wherein said reacting with a nitronium source takes place at a temperature ranging from about −80° C. to about 120° C.
12. The method according to claim 8, further comprising the steps of:
performing difluoramination, in the presence of a strong acid, on a tetrahydropyrimidin-5(4H)-one having a formula selected from the group consisting of:
Figure US20020007063A1-20020117-C00013
 and
recovering said 5,5-bis(difluoramino)hexahydro-1,3-disulfonylpyrimidine;
wherein R2 is selected from the group consisting of hydrogen, C1-C2 alkyl, and protected hydroxymethyl and 1,2 ethanediyl; and
wherein Z1 of halosulfonyl, polyhaloalkanesulfonyl, polyhaloarenesulfonyl, a regioisomer of fluoroarenesulfonyl, polyhaloarenesulfonyl, a regioisomer of cyanoarenesulfonyl, polycyanoarenesulfonyl, a regioisomer of nitroarenesulfonyl, and polynitroarenesulfonyl.
13. The method according to claim 12, wherein said difluoramination takes place at a temperature ranging from about −40° C. to about 100° C.
14. The method according to claim 12 wherein said strong acid is selected from the group consisting of difluorosulfamic acid and sulfuric acid, difluorosulfamic acid, anhydrous sulfuric acid, fluorosulfonic acid, and any combination thereof.
15. A pyrimidine having a formula selected from the group consisting of:
Figure US20020007063A1-20020117-C00014
wherein R2 is selected from the group consisting of hydrogen, C1-C2 alkyl, protected hydroxymethyl and 1,2 ethanediyl; and
wherein Z1 is selected from the group consisting of halosulfonyl, polyhaloalkanesulfonyl, polyhaloarenesulfonyl, a regioisomer of fluoroarenesulfonyl, polyhaloarenesulfonyl, a regioisomer of cyanoarenesulfonyl, polycyanoarenesulfonyl, a regioisomer of nitroarenesulfonyl, and polynitroarenesulfonyl.
16. A propanediamine having a formula:
Figure US20020007063A1-20020117-C00015
wherein R3 is selected from the group consisting of hydrogen, C1-C2 alkyl, and 1-(difluoramino)alkyl; and
wherein Z1 is selected from the group consisting of halosulfonyl, polyhaloalkanesulfonyl, polyhaloarenesulfonyl, a regioisomer of fluoroarenesulfonyl, polyhaloarenesulfonyl, a regioisomer of cyanoarenesulfonyl, polycyanoarenesulfonyl, a regioisomer of nitroarenesulfonyl, and polynitroarenesulfonyl.
17. A propanediamine having a formula:
Figure US20020007063A1-20020117-C00016
wherein R2 is selected from the group consisting of hydrogen, C1-C2 alkyl, substituted alkyl, halo, and nitro; and
wherein Z1 is selected from the group consisting of halosulfonyl, polyhaloalkanesulfonyl, polyhaloarenesulfonyl, a regioisomer of fluoroarenesulfonyl, polyhaloarenesulfonyl, a regioisomer of cyanoarenesulfonyl, polycyanoarenesulfonyl, a regioisomer of nitroarenesulfonyl, and polynitroarenesulfonyl.
US09/911,640 2000-02-16 2001-07-23 Electronegatively substituted pyrimidines and intermediates leading to RNFX Expired - Fee Related US6395899B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/911,640 US6395899B2 (en) 2000-02-16 2001-07-23 Electronegatively substituted pyrimidines and intermediates leading to RNFX

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/505,127 US6310204B1 (en) 2000-02-16 2000-02-16 5,5-bis(difluoramino)hexahydro-1,3-dinitropyrimidine (RNFX) and certain electronegatively substituted pyrimidines
US09/911,640 US6395899B2 (en) 2000-02-16 2001-07-23 Electronegatively substituted pyrimidines and intermediates leading to RNFX

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/505,127 Division US6310204B1 (en) 2000-02-16 2000-02-16 5,5-bis(difluoramino)hexahydro-1,3-dinitropyrimidine (RNFX) and certain electronegatively substituted pyrimidines

Publications (2)

Publication Number Publication Date
US20020007063A1 true US20020007063A1 (en) 2002-01-17
US6395899B2 US6395899B2 (en) 2002-05-28

Family

ID=24009129

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/505,127 Expired - Fee Related US6310204B1 (en) 2000-02-16 2000-02-16 5,5-bis(difluoramino)hexahydro-1,3-dinitropyrimidine (RNFX) and certain electronegatively substituted pyrimidines
US09/911,640 Expired - Fee Related US6395899B2 (en) 2000-02-16 2001-07-23 Electronegatively substituted pyrimidines and intermediates leading to RNFX

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/505,127 Expired - Fee Related US6310204B1 (en) 2000-02-16 2000-02-16 5,5-bis(difluoramino)hexahydro-1,3-dinitropyrimidine (RNFX) and certain electronegatively substituted pyrimidines

Country Status (1)

Country Link
US (2) US6310204B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7145003B1 (en) 2003-11-24 2006-12-05 The United States Of America As Represented By The Secrectary Of The Navy Process for synthesizing 1,5 dinosyl-3,3,7,7-tetrakis(difluoramino)octahydro-1,5-diazocine (DNTDFD)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417355B1 (en) * 2001-04-11 2002-07-09 The United States Of America As Represented By The Secretary Of The Navy Geminal-dinitro-1-5 diazocine derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7145003B1 (en) 2003-11-24 2006-12-05 The United States Of America As Represented By The Secrectary Of The Navy Process for synthesizing 1,5 dinosyl-3,3,7,7-tetrakis(difluoramino)octahydro-1,5-diazocine (DNTDFD)

Also Published As

Publication number Publication date
US6310204B1 (en) 2001-10-30
US6395899B2 (en) 2002-05-28

Similar Documents

Publication Publication Date Title
Maryanoff et al. A convenient synthesis of guanidines from thioureas
Koppes et al. Synthesis and structure of some peri-substituted 2, 4, 6, 8-tetraazabicyclo [3.3. 0] octanes
EP1406905B1 (en) Water- and organic-soluble cucurbituril derivatives, their preparation methods, their separation methods and uses
EP2734507B1 (en) Process for the synthesis of n-substituted cyclic alkylene ureas
US6310204B1 (en) 5,5-bis(difluoramino)hexahydro-1,3-dinitropyrimidine (RNFX) and certain electronegatively substituted pyrimidines
CA2434300A1 (en) Synthesis of temozolomide and analogs
Kornet Synthesis and anticonvulsant activity of 3‐alkyl‐3, 4‐dihydro‐2 (1H)‐quinazolinones
US3375259A (en) Difluoramino compounds
US6417355B1 (en) Geminal-dinitro-1-5 diazocine derivatives
Zolfaghari et al. Surfactant TBAB as a Catalyst for the Synthesis of 3, 4-Dihydropyrimidine Derivatives
US5831099A (en) Compounds of 1,5-disubstituted-3,7 diaza bicyclo 3.3.0! octanes and products containing the same
Ponomarenko et al. Glycoluril and Its Chemical Properties
Klayman et al. 2-Amino-2-thiazoline. VIII. Nonregioselective reaction of 2-amino-2-thiazoline with benzoyl isothiocyanate to give a thermally unstable thiourea and a thiazolotriazine
US7632943B1 (en) Method for making 3,3,7,7-tetrakis(difluoramino)octahydro-1,5-dinitro-1,5-diazocine (HNFX)
US7563889B1 (en) 3,3,7,7,-tetrakis(difluoramino)octahydro-1,5-diazocinium salts and method for making the same
KR100586671B1 (en) Method for preparing 5-substituted oxazole compound and 5-substituted imidazole compound
Ryzhkova et al. Multicomponent synthesis of 1, 4-dihydropyridine-3, 5-dicarbonitriles
Luk'yanov et al. N, N′-Diacylated imidazolidines and hexahydropyrimidines
US8444783B1 (en) 3,3,7,7-tetrakis(difluoramino)octahydro-1,5-diazocinium salts
Vinogradova et al. Synthesis of hybrid molecules based on thioglycolurils and 1, 2, 5-oxadiazoles via the Eschenmoser sulfide contraction
Khodairy et al. Synthesis of New Fused and Spiro 1, 5‐Benzodiazepines
Krapcho et al. Acridizinium salts. Preparation from 1-(benzylic)-2-formyl and 1-(benzylic)-2-acetyl pyridinium bromides and ring-openings reactions with nucleophilic reagents
Hrabalek et al. Synthesis of unsymmetrical sulfides derived from tetrazole-5-thiols
Mussons et al. Dibenz [c, h] acridine receptors for dibutylmalonic acid. Decarboxylative catalytic activity
Glukhareva et al. Reactions of 5-dialkylamino-1, 2, 3-thiadiazole-4-carbaldehydes with amines as a method for the synthesis of 1, 2, 3-triazole-4-carbothioamides

Legal Events

Date Code Title Description
REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20060528